257 related articles for article (PubMed ID: 9694923)
1. Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: antagonist effects of SR 141716A.
Vivian JA; Kishioka S; Butelman ER; Broadbear J; Lee KO; Woods JH
J Pharmacol Exp Ther; 1998 Aug; 286(2):697-703. PubMed ID: 9694923
[TBL] [Abstract][Full Text] [Related]
2. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
McMahon LR
J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
[TBL] [Abstract][Full Text] [Related]
3. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
McMahon LR; Koek W
Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486
[TBL] [Abstract][Full Text] [Related]
4. Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys.
Wiley JL; Lowe JA; Balster RL; Martin BR
J Pharmacol Exp Ther; 1995 Oct; 275(1):1-6. PubMed ID: 7562536
[TBL] [Abstract][Full Text] [Related]
5. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
McMahon LR
Psychopharmacology (Berl); 2006 Oct; 188(3):306-14. PubMed ID: 16953389
[TBL] [Abstract][Full Text] [Related]
6. The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2.
Darmani NA
Eur J Pharmacol; 2001 Oct; 430(1):49-58. PubMed ID: 11698062
[TBL] [Abstract][Full Text] [Related]
7. Interactions between μ-opioid receptor agonists and cannabinoid receptor agonists in rhesus monkeys: antinociception, drug discrimination, and drug self-administration.
Maguire DR; Yang W; France CP
J Pharmacol Exp Ther; 2013 Jun; 345(3):354-62. PubMed ID: 23536317
[TBL] [Abstract][Full Text] [Related]
8. The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats.
Solinas M; Panlilio LV; Antoniou K; Pappas LA; Goldberg SR
J Pharmacol Exp Ther; 2003 Jul; 306(1):93-102. PubMed ID: 12660305
[TBL] [Abstract][Full Text] [Related]
9. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice.
Smith SR; Terminelli C; Denhardt G
J Pharmacol Exp Ther; 2000 Apr; 293(1):136-50. PubMed ID: 10734163
[TBL] [Abstract][Full Text] [Related]
10. Combined Treatment with Morphine and Δ9-Tetrahydrocannabinol in Rhesus Monkeys: Antinociceptive Tolerance and Withdrawal.
Gerak LR; France CP
J Pharmacol Exp Ther; 2016 May; 357(2):357-66. PubMed ID: 26937020
[TBL] [Abstract][Full Text] [Related]
11. Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids.
Janoyan JJ; Crim JL; Darmani NA
Pharmacol Biochem Behav; 2002; 71(1-2):155-62. PubMed ID: 11812518
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoid modulation of intestinal propulsion in mice.
Colombo G; Agabio R; Lobina C; Reali R; Gessa GL
Eur J Pharmacol; 1998 Feb; 344(1):67-9. PubMed ID: 9570450
[TBL] [Abstract][Full Text] [Related]
13. R+-methanandamide inhibits tracheal response to endogenously released acetylcholine via capsazepine-sensitive receptors.
Nieri P; Martinotti E; Testai L; Adinolfi B; Calderone V; Breschi MC
Eur J Pharmacol; 2003 Jan; 459(1):75-81. PubMed ID: 12505536
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors.
Terranova JP; Michaud JC; Le Fur G; Soubrié P
Naunyn Schmiedebergs Arch Pharmacol; 1995 Nov; 352(5):576-9. PubMed ID: 8751088
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of hippocampal acetylcholine release by cannabinoids: reversal by SR 141716A.
Gessa GL; Mascia MS; Casu MA; Carta G
Eur J Pharmacol; 1997 May; 327(1):R1-2. PubMed ID: 9185841
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A.
Gessa GL; Casu MA; Carta G; Mascia MS
Eur J Pharmacol; 1998 Aug; 355(2-3):119-24. PubMed ID: 9760025
[TBL] [Abstract][Full Text] [Related]
17. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A.
Darmani NA
Neuropsychopharmacology; 2001 Feb; 24(2):198-203. PubMed ID: 11120402
[TBL] [Abstract][Full Text] [Related]
18. SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca2+ currents by reversal of tonic CB1 cannabinoid receptor activity.
Pan X; Ikeda SR; Lewis DL
Mol Pharmacol; 1998 Dec; 54(6):1064-72. PubMed ID: 9855635
[TBL] [Abstract][Full Text] [Related]
19. Modulation of cytokine responses in Corynebacterium parvum-primed endotoxemic mice by centrally administered cannabinoid ligands.
Smith SR; Terminelli C; Denhardt G
Eur J Pharmacol; 2001 Aug; 425(1):73-83. PubMed ID: 11672577
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid CB(1) receptor agonists increase rat cortical and hippocampal acetylcholine release in vivo.
Acquas E; Pisanu A; Marrocu P; Di Chiara G
Eur J Pharmacol; 2000 Aug; 401(2):179-85. PubMed ID: 10924924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
